Hong Kong stock anomaly | Rongchang Biotech (09995.HK) rose more than 4% as clinical research data on c-MET ADC treatment for non-small cell lung cancer was announced at the ASCO 2025 meeting.
Zhicheng Financial News App learned that Rongchang Biology (09995.HK) rose by more than 4%, as of the time of publication, it rose by 4.61% to HK$49.9 with a trading volume of HK$2.45 billion.
Latest
